Midatech Pharma Plcの利益マージン

Midatech Pharma Plcの利益マージンは何ですか。

Midatech Pharma Plcの利益マージンは-1,095.85%です。

利益マージンの定義は何ですか。



利益マージンは、収益性の尺度であり、収益の割合として純利益を求めることによって計算されます。

Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.

LSEのセクタHealth Careにおける利益マージンの企業と比べるMidatech Pharma Plc

Midatech Pharma Plcは何をしますか。

Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Midatech Pharma Plcと類似の利益マージン